fda warning peptides bpc 157 scientists flag concerns with as RFK Jr. tries to ease access : NPR FDA's Review Of Peptides Signals

Some research-model literature has examined combined administration of BPC-157 and TB-500 in tissue-repair contexts

By purchasing, you confirm that this product will be used solely for its intended laboratory research and reconstitution purposes

Other side effects Additional reported side effects include: Joint pain and water retention Muscle and joint aches Headaches and nausea Receptor desensitization with prolonged use Potential suppression of natural GH and IGF-1 production Who should avoid IGF-1 LR3 Certain groups should not use IGF-1 LR3: Anyone with active cancer or tumor history Those with severe insulin resistance or diabetes Pregnant or nursing women Anyone under 25 whose growth plates haven't closed Those with existing hormonal imbalances IGF-1 LR3 is not FDA-approved for general medical use and remains primarily a research compound

Read the label

Some research trials have been carried out in the use of infliximab biosimilars on people with other autoimmune conditions (rheumatoid arthritis and ankylosing spondylitis) but not on people with IBD